Loading clinical trials...

Biomarkers for Ventilator-associated Pneumonia | Clinical Trials | Clareo Health

RECRUITING

Biomarkers for Ventilator-associated Pneumonia

Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia

NCT05117125•Region Skane

Summary

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Admission to an intensive care unit
•Intubation within last 24 hours
•Anticipated mechanical ventilation of at least 48 hours

Exclusion Criteria

•FiO2 above 70% or PEEP above 15
•Ongoing infection of the lungs at admission to the ICU.
•Severely elevated or instable intracranial pressure.

Locations (5)

Vestre Viken

Drammen, Norway

Hospital de São Francisco Xavier

Lisbon, Portugal

Skåne University Hospital, Dept. of Infectious diseases

Lund, Sweden

Skåne university Hospital, ICU

Malmo, Sweden

Karolinska University Hospital, ICU

Solna, Sweden

Key Dates

Start Date

October 15, 2021

Primary Completion Date

December 31, 2026

Completion Date

December 31, 2028

Last Updated

November 15, 2024

Enrollment

1,000

ESTIMATED participants

Conditions

Pneumonia, Ventilator-Associated

Interventions

Heparin-binding protein

DIAGNOSTIC_TEST

Interleukin-26

DIAGNOSTIC_TEST

Microbiome

DIAGNOSTIC_TEST

Bacterial transcriptome

DIAGNOSTIC_TEST

Proteome

DIAGNOSTIC_TEST

Contacts

Magnus Paulsson, PhD MD

CONTACT

+46461775431 magnus.paulsson@med.lu.se

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

NCT07052604

Pneumonia, Ventilator-AssociatedStenotrophomonas Maltophilia+3 more

View study

ACTIVE_NOT_RECRUITINGNA

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation

NCT05405491

Pneumonia, Ventilator-AssociatedPneumonia, Hospital-Acquired+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Biomarkers for Ventilator-associated Pneumonia

Inclusion Criteria

Exclusion Criteria

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation

Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients

PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region

Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia

Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.